DarioHealth Corp.
About DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $7.4M
- Net income
- -$41.7M
- Total assets
- $110.1M
- Market cap
- $54.8M
- Gross margin
- 56.6%
- Operating margin
- -163.9%
- Net margin
- -186.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $22.4M
- Cost of revenue
- $9.7M
- Gross profit
- $12.7M
- Operating expenses
- $49.3M
- Operating income
- -$36.7M
- Income tax
- $105.0K
- Net income
- -$41.7M
- EPS (basic)
- $10.12
- EPS (diluted)
- $10.12
Balance sheet
- Total assets
- $110.1M
- Current assets
- $35.1M
- Total liabilities
- $42.2M
- Current liabilities
- $9.3M
- Shareholders’ equity
- $67.9M
Cash flow
- Operating cash flow
- -$25.9M
- Investing cash flow
- -$4.3M
- Financing cash flow
- $24.3M
- Net cash flow
- -$6.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $54.8M
- P/E ratio
- 0.7
- EPS (diluted)
- $10.12
- Shares outstanding
- 7.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 8, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $41.7M in FY2018.
- Revenue grew 9% from FY2021 to FY2025.
- Gross margin of 56.6%, net margin -186.6%.
- Trading 57% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 0.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DarioHealth Corp..
Write a review
News about DarioHealth Corp.
News & sentiment via Polygon.io
